Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.
ACTIV-6 is a clinical trial funded by the National Institutes of the Health (NIH). The purpose of the trial is the development of outpatient treatments for COVID-19:
“ACTIV-6 will evaluate whether certain drugs showing promise in small trials can pass the rigor of a larger trial.”
The trial has since been defined to study Ivermectin and stipulates that half of the volunteers receive no outpatient treatment for the disease. This is controversial given the evidence for the effectiveness of this medication.
The study lead, Susanna Naggie, stated earlier that the trial had received approval from the institutional review board (IRB) and when asked about the justification for the trial explained:
“…The IRB was comfortable with our summary of the evidence and stance that there has not been a definitive determination of the efficacy of ivermectin. Similarly, the NIH COVID Guideline recommendation is that there is insufficient evidence to recommend for or against ivermectin for COVID-19. There are a lot of interested sites. T...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).